|Titre :||Hepatitis C services at harm reduction centres in the European Union: a 28-country survey (2019)|
|Auteurs :||J. M. PERICAS ; D. J. BROMBERG ; D. OCAMPO ; E. SCHATZ ; I. WAWER ; P. WYSOCKI ; K. SAFREED-HARMON ; J. V. LAZARUS|
|Type de document :||Article : Périodique|
|Dans :||Harm Reduction Journal (Vol.16, n°20, 2019)|
|Article en page(s) :||10 p.|
|Discipline :||MAL (Maladies infectieuses / Infectious diseases)|
Thésaurus TOXIBASEENQUETE ; HEPATITE ; REDUCTION DES RISQUES ; PRISE EN CHARGE ; DEPISTAGE ; TEST ; TRAITEMENT ; ACCES AUX SOINS
Thésaurus GéographiqueEUROPE ; UNION EUROPEENNE
Background: In the context of the WHO’s 2016 Viral Hepatitis Strategy and the introduction of treatment that can cure more than 95% of cases with hepatitis C virus (HCV) infection, the European Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT) undertook a study in the member states of the European Union (EU). It aimed to determine service providers' understanding of the current services in their respective countries and the barriers experienced by PWID in accessing HCV testing, care and treatment services in their country.
Methods: In 2017, 38 purposively selected harm reduction service providers completed a 26-item English-language online survey addressing the availability, accessibility and funding of HCV services at harm reduction centres. HCV-related data and reported findings were extracted by country or by responding organization.
Results: Responses were received from all EU member states. Respondents from 23 countries reported that HCV tests are offered by harm reduction services in their countries, and eight countries reported that addiction specialists in their countries are able to prescribe HCV therapy. Almost half of the respondents (45%) said that their respective organizations had established referral systems with centres providing HCV treatment.
Conclusions: Not all EU member states have harm reduction services that provide HCV tests, and many do not have established referral systems with treatment providers. Moreover, the inability of addiction specialists to prescribe HCV treatment points to missed opportunities to make treatment more accessible. Further, discrepancies were noted between the available HCV services and stakeholders’ knowledge about their availability.
|Domaine :||Drogues illicites / Illicit drugs|
|Refs biblio. :||54|
|Affiliation :||Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Carrer Rossello, Barcelona, Spain|